Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study concluded that advancements in understanding the immunological mechanisms of alopecia areata have led to promising therapies, particularly JAK inhibitors and novel drug delivery systems, but further research is needed for clinical application.

This study found that patients with alopecia areata have a significantly higher risk of retinal abnormalities, suggesting common immune mechanisms, though the low absolute risk indicates that screening should be led by symptoms rather than done routinely.

This review highlights advancements in the understanding and treatment of alopecia areata, noting that the approval of oral Janus kinase inhibitors like baricitinib and ritlecitinib marks a significant development in managing severe cases of this autoimmune condition.

In this case report, a 77-year-old woman developed alopecia areata after discontinuing cemiplimab treatment for metastatic cutaneous squamous cell carcinoma, suggesting an immune-related adverse effect potentially linked to systemic immune activation.

This research aims to address gaps in understanding alopecia areata by evaluating the real-world effectiveness and safety of baricitinib, identifying predictors of therapeutic response, and exploring the long-term impact on life quality, including sexual health. Results are not reported in the abstract.

This review discusses the uncertain role of immune factors, particularly autoantibodies, in the development of alopecia areata and emphasizes that identifying key autoantigens could lead to targeted immunotherapies.

In this review, researchers conclude that immune imbalance between regulatory and cytotoxic T cells, along with activation of IFN-γ–MHC and IL-15–NK pathways, disrupts hair follicle immune privilege, suggesting pivotal mechanisms in alopecia areata development and potential targets for immunotherapeutic interventions.

In this single-cell transcriptomic study, researchers analyzed AA scalp samples and found distinct immune and nonimmune cell activation patterns, with elevated TH1/TH2 and JAK/STAT markers potentially contributing to hair follicle immune privilege disruption and disease severity.

This review highlights a disconnect between mechanistic insights and physiological relevance in preclinical models of hair loss disorders and suggests a shift toward more human-relevant systems could enhance translational research, despite limitations in existing models like transgenic mice and xenografts.

This review synthesizes recent advancements in clinical trichology, highlighting updates on androgenetic alopecia treatments like low-dose oral minoxidil, 5α-reductase inhibitors, and other therapeutic options for various alopecia types, including telogen/anagen effluvium and alopecia areata, and detailed approaches for scarring alopecias and pediatric trichology.

This review article explores the potential systemic nature of alopecia areata, highlighting the association with ocular abnormalities and suggesting that shared pathogenic pathways may lead to eye symptoms occurring at younger ages than usual.

BTNL2 helps protect hair follicles from immune attacks.

Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.

CBD can help hair grow by supporting scalp health and reducing inflammation.

This study observed that in human scalp hair follicles, BTNL2 expression is lower in stressed conditions, which correlates with increased cytotoxic activity by gamma/delta and CD8+ T cells, suggesting a possible role for BTNL2 in controlling immune responses relevant to alopecia areata.

Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.

This study found that autologous Foxp3+ γδTregs, when tested in human scalp hair follicle models and mouse xenotransplants, can both prevent and treat alopecia areata by reducing immune privilege collapse and lymphocytic infiltration, suggesting their potential as a novel cell-based therapy for the disease.

In this observational study, researchers found that alopecia areata is associated with specific trichoscopic features, such as black dots, yellow dots, and vellus hair, and highlighted trichoptilosis as a potential overlap feature with other hair disorders, suggesting a need for further differentiation between these conditions.

This paper discusses the balance between target tissue destruction and recovery rates in autoimmune diseases, proposing that high recovery rates are crucial for remitting-relapsing patterns, while exercise might not be neuroprotective in secondary progressive multiple sclerosis.

This study reviews the role of hair follicles in the development, symptoms, and treatment options for vitiligo and alopecia areata, aiming to enhance understanding of their involvement in these autoimmune conditions and explore potential therapies.

γδT cells can protect hair follicles from alopecia areata and promote hair regrowth.

This study found that γδTregs can prevent and treat alopecia areata in a mouse model with human scalp transplants, suggesting potential for cell-based therapies in autoimmune diseases like alopecia.

In this study, researchers explored the immunological mechanisms involved in alopecia areata and suggested that targeting immune responses, particularly using JAK inhibitors and other immunomodulatory drugs, could help achieve stable remission and improve patients' quality of life.

In this study, γδTregs showed potential as a cell-based therapy for alopecia areata by preventing hair loss and promoting hair regrowth in humanized AA models.

Linalool in fragrances may harm hair follicles and contribute to hair loss.

This study examines the similarities and differences in the pathogenesis of autoimmune conditions alopecia areata and vitiligo, highlighting shared features like immune cell involvement and cytokine pathways, while noting differing immune responses in skin and hair.

In this case report, a woman developed severe alopecia areata approximately one year after starting belimumab for systemic lupus erythematosus, with hair loss improving upon discontinuation of the drug, suggesting a possible connection between belimumab and immune-mediated hair loss.

This research examined the transcriptional landscape of quiescent melanocyte stem cells (qMcSCs) in adult female mice, revealing significant heterogeneity within this cell population and identifying novel subpopulations that vary in immune privilege regulation, melanocyte differentiation potential, and neural crest potential.

This article provides a review of alopecia areata, highlighting the development of diagnostic and therapeutic algorithms that consider factors such as age, disease severity, and quality of life, but it reports no new clinical findings.

This study found that γδTregs significantly reduced autoimmune effects in humanized alopecia areata models, suggesting their potential as a novel cell-based therapeutic approach for managing the condition.